Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more
Apex Biotechnology Corp (1733) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.003x
Based on the latest financial reports, Apex Biotechnology Corp (1733) has a cash flow conversion efficiency ratio of 0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$5.19 Million) by net assets (NT$1.81 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apex Biotechnology Corp - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Apex Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Apex Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apex Biotechnology Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pensana Plc
PINK:PNSPF
|
N/A |
|
Enea AB (publ)
F:EED5
|
0.003x |
|
Saigon Thuong Tin Real Estate JSC
VN:SCR
|
-0.217x |
|
Grupo Ecoener S.A.
MC:ENER
|
0.052x |
|
AimCore Technology Co Ltd
TWO:3615
|
0.041x |
|
Wuling Motors Holdings Limited
PINK:WLMTF
|
-0.819x |
|
Quisitive Technology Solutions Inc
OTCQX:QUISF
|
0.061x |
|
DSK Co. Ltd
KQ:109740
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Apex Biotechnology Corp (2002–2024)
The table below shows the annual cash flow conversion efficiency of Apex Biotechnology Corp from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.82 Billion | NT$328.67 Million | 0.180x | +40.52% |
| 2023-12-31 | NT$1.80 Billion | NT$230.39 Million | 0.128x | +775.71% |
| 2022-12-31 | NT$1.82 Billion | NT$26.62 Million | 0.015x | -85.73% |
| 2021-12-31 | NT$1.75 Billion | NT$179.87 Million | 0.103x | -39.83% |
| 2020-12-31 | NT$1.65 Billion | NT$280.60 Million | 0.170x | -38.20% |
| 2019-12-31 | NT$1.68 Billion | NT$462.52 Million | 0.276x | +571.12% |
| 2018-12-31 | NT$1.64 Billion | NT$67.57 Million | 0.041x | -3.39% |
| 2017-12-31 | NT$1.66 Billion | NT$70.83 Million | 0.043x | -75.27% |
| 2016-12-31 | NT$1.73 Billion | NT$298.06 Million | 0.172x | -29.67% |
| 2015-12-31 | NT$1.93 Billion | NT$472.15 Million | 0.245x | +70.64% |
| 2014-12-31 | NT$1.87 Billion | NT$267.60 Million | 0.143x | -43.20% |
| 2013-12-31 | NT$1.92 Billion | NT$484.77 Million | 0.252x | -0.31% |
| 2012-12-31 | NT$2.01 Billion | NT$509.67 Million | 0.253x | +62.08% |
| 2011-12-31 | NT$1.75 Billion | NT$273.45 Million | 0.156x | -45.31% |
| 2010-12-31 | NT$1.63 Billion | NT$465.59 Million | 0.286x | +7.41% |
| 2009-12-31 | NT$1.47 Billion | NT$391.29 Million | 0.266x | +12.09% |
| 2008-12-31 | NT$1.26 Billion | NT$299.96 Million | 0.237x | -12.21% |
| 2007-12-31 | NT$1.35 Billion | NT$364.62 Million | 0.270x | -18.07% |
| 2006-12-31 | NT$1.10 Billion | NT$363.71 Million | 0.330x | +39.47% |
| 2005-12-31 | NT$896.93 Million | NT$212.14 Million | 0.237x | -6.29% |
| 2004-12-31 | NT$865.91 Million | NT$218.54 Million | 0.252x | -29.66% |
| 2003-12-31 | NT$842.42 Million | NT$302.25 Million | 0.359x | +221.73% |
| 2002-12-31 | NT$712.76 Million | NT$79.49 Million | 0.112x | -- |